[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351833-105":59,"doc-detail-351833-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhancing-immunotherapeutic-response-in-colorectal-cancer-with-a-neuropilin-1-targeting-tumor-penetrating-peptide","Enhancing Immunotherapeutic Response in Colorectal Cancer with a Neuropilin 1-Targeting Tumor-Penetrating Peptide","","Immune checkpoint inhibitors show durable benefit in a subset of colorectal cancers, but responses are largely limited to microsatellite instability–high (MSI-H) tumors. This study tested whether the tumor-penetrating peptide iRGD improves anti–PD-1 therapy efficacy and assessed the clinical relevance of neuropilin 1 (NRP1) expression. In syngeneic mouse models, iRGD combined with anti–PD-1 increased intratumoral CD8+ T-cell abundance and function, including in tumors lacking tumor-cell NRP1, indicating a stromal role. In 110 stage III patients, NRP1 expression across tumor and stromal compartments correlated with poor survival, positioning stromal NRP1 as a prognostic marker and actionable entry point for iRGD-based ICI strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancing-immunotherapeutic-response-in-colorectal-cancer-with-a-neuropilin-1-targeting-tumor-penetrating-peptide/351833/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancing-immunotherapeutic-response-in-colorectal-cancer-with-a-neuropilin-1-targeting-tumor-penetrating-peptide/351833.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are immune checkpoint inhibitors limited in colorectal cancer?","Question",{"text":112,"@type":113},"Clinical benefit of ICIs in colorectal cancer is largely confined to MSI-H tumors, while most patients have limited overall responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does iRGD enhance anti–PD-1 therapy efficacy?",{"text":117,"@type":113},"The study shows that combining iRGD with anti–PD-1 increases intratumoral CD8+ T-cell abundance and improves their function, along with enhanced antitumor effects.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does neuropilin 1 (NRP1) play in iRGD activity?",{"text":121,"@type":113},"iRGD activity persisted even when tumor cells lacked NRP1, indicating stromal NRP1—particularly in endothelial and stromal compartments—mediates the therapeutic effect.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351833,1790251642,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0619](https://doi.org/10.1158/2767-9764.CRC-25-0619)  OPEN ACCESS  \nEnhancing Immunotherapeutic Response in Colorectal Cancer with a Neuropilin 1–Targeting Tumor-Penetrating Peptide  \nAtsushi Fukugaki1, Shigeo Hisamori1, Dean Thumkeo2, Hotaka Kawai3, Yugo Matsui1, Yuki Teramoto4, Yoshihisa Okuchi5, Atsuhito Omori1, Norio Miyamura6, Yukihito Kuroda6, Kazuki N. Sugahara6, and Kazutaka Obama1  \n􀀶  \nABSTRACT  \nImmune checkpoint inhibitors (ICI) provide durable responses in a subset of colorectal cancers, yet benefit is largely confined to microsatellite instability–high (MSI-H) tumors. We investigated whether the tumor-penetrating peptide iRGD enhances anti–programmed cell death protein 1 (PD-1) treatment efficacy and examined the clinical relevance of neuropilin 1 (NRP1) expression. Syngeneic mouse models (MSI-H MC38 and microsatellite-stable CT26) were treated with an anti–PD-1 antibody and iRGD. Tumor cell and stromal NRP1 contributions were compared using NRP1-knockout colorectal cancer cell lines. NRP1 expression was analyzed using immunohistochemistry in a consecutive cohort of 110 patients with stage III colorectal cancer who underwent curative surgery. iRGD and anti– PD-1 antibody combination therapy enhanced antitumor effects in both colorectal cancer models, accompanied by increased intratumoral CD8+ T-cell abundance and improvements in their function. This effect persisted in tumors lacking tumor cell NRP1, suggesting that stromal NRP1 played a key role in mediating iRGD activity.  \nIn pathologic specimens from patients with colorectal cancer, widespread NRP1 expression was noted across tumor cells, the stromal compartment, and the vasculature, suggesting potential applicability of iRGD-based therapy in human colorectal cancer. Notably, stromal NRP1 expression was associated with poor overall and disease-free survival. Collectively, these findings position stromal NRP1 as a prognostic marker and an actionable entry point for iRGD-based ICI strategies, providing a strong rationale for their clinical development to extend the benefits of ICIs to broader colorectal cancer populations.  \nSignificance: We demonstrated that iRGD enhanced anti–PD-1 therapy efficacy in colorectal cancer models, improving intratumoral permeability and antitumor immune responses. NRP1 is broadly expressed across tumor compartments, and stromal, particularly endothelial, NRP1 is a key mediator ofiRGD activity, associated with poor prognosis, representing a potential therapeutic entry point.  \n1Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 2Department of Immunopharmacology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 3Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. 4Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 5Department of Gastroenterological Surgery and Oncology, Medical Research Institute Kitano Hospital, Osaka, Japan. 6Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.  \nK. N. Sugahara and K. Obama contributed equally to this article and share senior authorship.  \nCorresponding Author: Shigeo Hisamori, Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507,  \nJapan. E-mail: [hisamori@kuhp.kyoto-u.ac.jp](hisamori@kuhp.kyoto-u.ac.jp)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-25-0619  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2026 The Authors; Published by the American Association for Cancer Research  \nIntroduction  \nColorectal cancer is a leading cause of cancer-related death worldwide ( 1) . Although clinical outcomes have improved with significant","cbCaiuFJ17HAkf9f","https://ap.wps.com/l/cbCaiuFJ17HAkf9f","pdf",31296784,12,"English","# Abstract\n## Study rationale and background\n## Tumor-penetrating peptide iRGD and NRP1 biology\n## Immune checkpoint inhibitor limitations in CRC\n## Combination strategy and evaluation approach","[{\"question\":\"Why are immune checkpoint inhibitors limited in colorectal cancer?\",\"answer\":\"Clinical benefit of ICIs in colorectal cancer is largely confined to MSI-H tumors, while most patients have limited overall responses.\"},{\"question\":\"How does iRGD enhance anti–PD-1 therapy efficacy?\",\"answer\":\"The study shows that combining iRGD with anti–PD-1 increases intratumoral CD8+ T-cell abundance and improves their function, along with enhanced antitumor effects.\"},{\"question\":\"What role does neuropilin 1 (NRP1) play in iRGD activity?\",\"answer\":\"iRGD activity persisted even when tumor cells lacked NRP1, indicating stromal NRP1—particularly in endothelial and stromal compartments—mediates the therapeutic effect.\"}]","Enhancing Immunotherapeutic Response in Colorectal Cancer with a Neuropilin 1-Targeting Tumor-Penetrating Peptide | PDF",1790096253,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee87345825147c538b9144a8aec5aaf3.webp",983,1263,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c49c7216ce4c0f6fe51b3925b5087b61.webp",982,1262,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7973bb40e6832d434a4d30a31fde3bd.webp",981,1261,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5ccec2df0996425b067b2920a0039ee.webp",980,1259]